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BACKGROUND: Mter the successful evolution of he-
patic transplantation during the last decade, small bowel 
and multivisceral transplantation remains the sole elu-
sive achievement for the next era of transplant sur-
geons. Until recently, and for the last thirty years, 
the results of the sporadic attempts of intestinal trans-
plantation worldwide were discouraging because of 
unsatisfactory graft and patient survival. The experi-
mental and clinical demonstration of the superior 
therapeutic efficacy of FK 506, a new immunosup-
pressive drug, ushered in the current era of small 
bowel and multivisceral transplantation with initial 
promising results. 
STUDY DESIGN: Forty-three consecutive patients with 
short bowel syndrome, intestinal insufficiency, or ma-
lignant tumors with or without associated liver disease, 
were given intestinal (n=15), hepatic and intestinal 
(n=21), or multivisceral allografts that contained four 
or more organs (n=7). Treatment was with FK 506 
based immunosuppression. The ascending and right 
transverse colon were included with the small intestine 
in 13 of the 43 grafts, almost evenly distributed be~K 
tween the three groups. 
RESULTS: Mter six to 39 months, 30 of the 43 patients 
are alive, 29 bearing grafts. The most rapid conva-
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lescence and resumption of diet, as well as the highest 
three month patient survival (100 percent) and graft 
survival (88 percent) were with the isolated intestinal 
procedure. However, this advantage was slowly eroded 
during the f"rrst two postoperative years, in part be-
cause the isolated intestine was more prone to rejec-
tion. By the end of this time, th~ best survival rate 
(86 percent) was with the multivisceral procedure. With 
all three operations, most of the patients were able 
to resume diet and discontinue parenteral alimenta-
tion, and in the best instances, the quality of life 
approached normal. However, the surveillance and 
intensity of care required for these patients for the 
f"rrst year, and in most instances thereafter, was very 
high, being far more than required for patients having 
transplants of the liver, kidney or heart. 
CONCLUSIONS: Although intestinal transplantation has 
gone through the feasibility phase, strategies will be 
required to increase its practicality. One possibility 
is to combine intestinal transplantation with contem-
poraneous autologous bone marrow transplantation. 
J. Am. Coll. Surg., 1994, 179: 385-400. 
ALTHOUGH the intestine was one of the first organs 
to be transplanted experimentally (1, 2), it was 
the last to be grafted successfully in humans (3-
6). It was considered to be a "forbidd.en" organ 
for nearly three decades (7). After demonstrating 
the superior therapeutic index of the new im-
munosuppressive drug FK 506 for experimental 
intestinal and multivisceral transplantation (8, 9), 
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FIG. 1. Isolated intestinal transplantation including one-half of the colon (main figure) or the 
small intestine only (left insert) is shown. Graft venous outflow is drained end-to-side (main 
figure) or end-to-end (right insert) into the host portal system. IVC, Inferior vena cava. 
these procedures were used frequently at the Pitts-
burgh Transplant Institute (10-14). We report 
herein our experience with 43 consecutive pa-
tients who were given 45 intestinal grafts, either 
alone, in continuity with the donor liver, or as 
part of a multivisceral composite of abdominal 
splanchnic organs. 
MATERIALS AND METHODS 
Patient population. The 43 patients ·were treated 
between May 2, 1990 and April 15, 1993. Twenty-
one of the 43 patients were adults 19 to 58 
years of age and 22 were children who were 0.5 
to 15.5 years of age. All patients, except two 
who were given multivisceral grafts, were on total 
TABLE I.-CLINICAL FEATURES OF THE INTESTINAL RECIPIENTS 
Total population, n=43 
No. of patients 
Children. ........ 22 
Adults .. 21 
Sex 
Male .. 22 
Female. 21 
Age, y* 
Children 3.5±3.7 
Adults ........ 33.3±10.2 
Duration of TPN, mo* 37±34 
Serum bilirubin, mg/dL* .... lI±13 
Graft 
Cold ischemia time, h* .... 7.4±2.2 
Positive cytotoxic cross-match . 2 (4.7) 
Small intestine 
Without colon 30 
With colon ... 13 
Follow-up, mo* 15±10 
*Mean plus or minus standard deviation. 
Multivisceral: stomach, duodenum, pancreas, intestine, and liver. 
TPN, Total parenteral nutrition; y, year; h, hour, and mo, month. 
Numbers in parentheses are percentages. 
Isolated intestine, n=15 Intestine plus liver, n=21 Multivisceral, n-7 
5 15 2 
10 6 5 
7 11 4 
8 10 3 
5.1±4.4 3.0±3.7 3.2±1.9 
.. 
36.6±11.4 27.9±9.1 33.2±7.4 
52±47 28±21 26±20 
l.O±O.6 19±14 5±9 
6.5±2.0 7.9±2.0 7.8±2.5 
o (0) 2 (9.5) o (0) 
10 17 3 
5 4 4 
14±7 16±12 1l±8 
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FIG, 2, Hepatic and intestinal transplantation including part of the colon (main figure) or 
with small intestine only (left insert) are shown. The host portal vein is drained into the graft 
portal vein when possible, but in one-third of the instances, this blood was diverted into the 
vena cava (right insert). CA, Celiac artery; pv, portal vein; IVC, inferior vena cava, and SJI.1A, 
superior mesenteric artery. . 
parenteral nutrition (TPN) for one to 132 months 
before transplantation and all had had more than 
one episode of sepsis, damage to the liver or 
other TPN-related complications (Table I). Two 
additional adult patients bled to death as a result 
of massive venous collaterals during preliminary 
dissection of the native organs, and they were 
excluded from the analyses. Both were candidates 
for multivisceral transplantation because of ex-
tensive thrombosis of the splanchnic and hepatic 
venous systems concomitant with hepatic failure. 
The causes of intestinal failure and indications 
for the three different operations are given in 
Table II. The state of the liver was the most 
critical factor in the choice of procedure. 
Intestine only (n=15)-The isolated intestinal 
recipients were free of jaundice, although most 
had minor hepatic function abnormalities. Fre-
quent central line sepsis and increasing difficulty 
TABLE II,-CAUSES OF INTESTINAL FAILURE AND INDICA-
TIONS FOR INTESTINAL TRANSPLANTATION 
Intestine 
Cause Intestine plus liver Multivisceral 
ADULTS. N·21 
Crohn's disease .. 5 1 0 
Abdominal lrauma , , , 2 2 0 
Celiac artery occlusion 0 0 3* 
S,MA thrombosis , .. 0 2 0 
Desmoid tumor. ... 1 1 0 
Surgical adhesions . . . 2 0 0 
Metastatic gastrinoma -. ' 0 0 1 
Budd-Chiari syndrome . 0 0 1 
CHILDREN, N·22 
Gastroschisis . . . . . . . 1 5 0 
Necrotizing enterocolitis 0 4 0 
Volvulus ......... 1 3 0 
Intestinal atresia 1 2 0 
Microvillus disease 1 1 0 
Pseudo-obstruction 1 0 1 
Multiple polyposis 0 0 1 
'These patients had short-gut syndrome due to concomitant superior mes-
enteric artery thrombosis from protein S deficiency, n=l; antithrombin III 
deficiency. n=l. or from unknown cause, n=l. 
Multiviscernl: stomach, duodenum, pancreas, intestine, and liver, 
S.M.A, Superior mesenteric artery. 
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FIG. 3. Depicted is a full multivisceral operation including 
the ascending and right transverse colon. Note that pylo-
roplasty or pyloromyotomy was performed and that bile 
flow was temporarily decompressed in all instances. 
in obtaining central access for intravenous nu-
trition had been frequent problems. 
Liver plus intestine (n==2l)-All patients un-
dergoing hepatic and intestinal transplantation 
were jaundiced and had other evidence of ad-
vanced liver disease (Table I). 
Multivisceral transplantation (n==7)-Six of these 
seven allografts included all of the usual mul-
tivisceral constituents. The liver was removed from 
the seventh multivisceral graft and used for an-
other recipient. In two of the five adult patients, 
deficiency of protein S and antithrombin III un-
derlay previous thrombosis of both the superior 
mesenteric artery and celiac axis. Because the 
liver is the source of these factors, its inclusion 
in the graft was mandatory although hepatic fail-
ure was not present. 
Transplantation procedures. All of the cadaveric 
donors were ABO blood group identical with 
the recipients. Human leukocyte antigen match-
ing was random and uniformly poor. The Iym-
phocytotoxic cross-match was positive in two pa-
tients (Table I). No attempts were made to alter 
the graft immunologic tissue with irradiation, an-
tilymphocyte preparations, or other modalities. 
An effort was made to eradicate fungal and bac-
terial contamination of the donor alimentary 
tract. 
The principles (15) as well as details (8-14, 
16, 17) of both the donor and recipient opera-
tions have been described elsewhere. The isolated 
intestinal grafts were arterialized from the aorta 
with superior mesenteric venous drainage into 
the native portal system (Fig. 1) when technically 
feasible (n==14 of 15). In 14 of the 21 intestinal 
and hepatic transplantations, the residual portal 
venous drainage from the host pancreas and other 
retained native organs was directed into the graft 
portal vein by portal-to-portal anastomosis (Fig. 
2). In the other seven, the residual recipient 
splanchnic venous bed was decompressed with 
a portacaval shunt (Fig. 2, right inset). Six of 
the multivisceral operations consisted of resection 
of the remaining host intra-abdominal viscera and 
the insertion of a full set of viscera minus the 
spleen (Fig. 3). In the seventh instance, the host 
liver was retained. 
In most instances with all three procedures, 
the colon was discarded. However, in 13 patients, 
the ascending colon, with or without the trans-
verse colon, was included with the small bowel 
graft with a nearly equal frequency in the three 
cohorts (n==4 or 5 in each) (Table I). The cold 
ischemia times after initial flushing with Univer-
sity of Wisconsin solution were 7.4±2.2 (standard 
deviation [SD]) hours (range of 2.8 to 11.1 hours) 
with no significant difference (p==O.I) between the 
three different types of visceral grafts (Table I). 
Reconstruction of gastrointestinal continuity was 
with conventional techniques. Four different types 
of enterostomies were used for early decompres-
sion and monitoring o( the intestinal allograft. 
Initially, both ends of the graft were exteriorized 
by the chimney method. After the first five cases, 
the chimney was used onlY at the distal end 
(Figs. 1 and 2) and a tube jejunostomy, with or 
without gastrostomy, was used proximally for de-
compression as well as tube feeding as soon as 
possible (Figs. 1, 2, and 3). In the first ten of 
the 13 patients who received colon as well as 
small bowel, an end transverse colostomy was 
constructed of the allograft colon, but the last 
three patients had a distal ileal loop exteriorized 
by the Bishop-Koop principle plus a distal colo-
colostomy (Figs. 1, 2, and 3). The various enteros-
tomies were taken down with an extraperitoneal 
technique two to 11 months after transplantation. 
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FIG. 4. FK 506 plasma trough levels and FK 506 and prednisone doses in 
the three patient cohorts. Values are mean plus or minus standard error of 
the mean. 
Biliary reconstruction for the recipients of he-
patic and intestinal transplantation was with 
choledochojejunostomy (Fig. 2). The bile flow 
was temporarily decompressed with a cannula in 
the graft common bile duct in the multivisceral 
recipients in an attempt to minimize the risk of 
postoperative pancreatitis. The cannula was placed 
through the cystic duct (Fig. 3). Cholecystectomy 
was performed in all native and allograft livers. 
Management. Immunosuppression-Intravenous 
FK 506, steroids, and Prostin®, Upjohn, Kalama-
zoo, MI (prostaglandin E1 [PGE1]) were begun 
intraoperatively as previously described (11, 18, 
19). Enteral administration of FK 506 was begun 
one to two weeks after transplantation, with sev-
eral days of overlap with intravenous treatment. 
The 12 hour plasma FK 506 trough levels and 
the doses necessary to maintain these levels are 
illustrated in Figure 4. 
Except for the first eight recipients, PGE1 was 
begun intraoperatively at a beginning dose of 
0.2 mg per kg per hour and gradually increased 
to 0.6 to 0.8 mg per kg per hour and continued 
until intravenous FK 506 was stopped. High peri-
operative steroid doses were gradually reduced 
(Fig. 4) or stopped when possible, particularly 
in the pediatric recipients. A low dose ofImuran®, 
Burroughs Wellcome, Research Triangle Park, NC 
(azathioprine) (l to 2 mg per kg per day) was 
given to 22 patients at some time during the 
postoperative period. 
Augmented immunosuppressive therapy was in-
itiated during rejection episodes, based on their 
severity. A steroid bolus was given and FK 506 
dose was increased when this was possible without 
----------------------
---------------
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nephrotoxicity. A steroid recycle for five days or 
a seven day course of OKT3, or both, were backup 
options. 
Prophylaxis of infection-Selective intestinal de-
contamination was used for four to six weeks 
postoperatively and resumed later during mod-
erate to severe rejection episodes (20). Systemic 
antibiotics were given prophylactically for the first 
five days, as well as subsequently, if indicated 
by the results of blood and body fluid cultures. 
Frequen t cultures of blood, ostomy discharge, 
wound, urine, stool, and sputum were done to 
monitor changes in flora, and to obtain direct 
evidence of active infection or translocation. 
Chronic _ viral and protozoal prophylaxis was 
with Zovirax®, Burroughs Wellcome (acyclovir) for 
cytomegalovirus (CMV) and Bactrim®, Roche 
Laboratories, Nutley, NJ (timethoprim and sul-
famethoxazole) for pneumocystis carinii. Because 
of the high incidence of CMV enteritis in re-
cipients who received CMV positive grafts, Cy-
tovene®, Syntex, Palo Alto, CA (gancyclovir) was 
given prophylactically for three months after 
transplantation in the last cases. If severe CMV 
infection occurred despite prophylaxis, Foscavir@, 
Astra USA, Inc., Westboro, MA (foscarnet) or 
CMV immunoglobulin "cytogam," or both, were 
added to the gancyclovir treatment. 
Nutrition-The preoperative TPN was contin-
ued postoperatively. After confirming the integ-
rity of the gastrointestinal anastomoses and partial 
recovery of the intestinal motility by the appro-
priate gastrointestinal contrast studies (usually at 
seven to ten postoperative days), enteral feeding 
with a jejunal tube was commenced with peptamen 
(Clintec Nutrition Co., Deerfield, IL) and TPN 
was tapered gradually. Peptamen is an isotonic 
elemental diet that contains peptide-based protein, 
medium-chain triglycerides, and glutamine. Four 
to six weeks after transplantation, peptamen was 
converted in childreri to compleat B (Sandoz, 
East Hanover, NJ), a lactose and gluten-free diet 
that contains dietary fibers to promote normali-
zation of intestinal motility function. Enteral feed-
ings were gradually decreased with a reciprocal 
increase in oral intake. Opiates, loperamide, and 
kaolin-pectin mixture were used for patients who 
had high stomal output or diarrhea. Prokinetic 
agents were given to patients with gastrointestinal 
dysmotility. 
Graft monitoring. Rejection-Graft rejection was 
diagnosed from clinical observations, endoscopic 
findings, and histopathologic studies of endoscopi-
cally-guided mucosal biopsies. Protocol graft en-
doscopy with random multiple mucosal biopsies 
(particularly of the ileum) was accomplished at 
least once per week for the first three months, 
monthly for the next three months, and every 
three to six months thereafter, and whenever it 
was clinically indicated. The clinical, endoscopic, 
and histologic criteria adopted for the diagnosis 
of intestinal allograft rejection were comprehen-
sively described elsewhere (12). Immunosuppres-
sion was adjusted accordingly. 
Function-Standard hepatic and pancreatic 
function tests were used to track the functional 
status of these organs. Contrast examinations of 
the gastrointestinal tract were performed to de-
termine the duration of gastric emptying, intes-
tinal transit time, and changes of mucosal fold-
ings (21). Oral FK 506 pharmacokinetic studies 
provided a direct measure of absorption after 
discontinuation of intravenous FK 506 doses. Ab-
sorption of d-xylose and fat was measured with 
the methods of Breiter and associates (22) and 
Amenta (23), respectively. Serum concentrations 
of protein, albumin, vitamins, minerals, and trace 
elements were measured frequently. Anthropometric 
measures included weight and upper arm measure 
ment of fat and muscle. 
Statistical analysis. Data were collected for the 
total population, pooled at first, and then strati-
fied according to the type of the transplanted 
graft. Values usually were expressed as the mean 
and SD. Survival time for patients was defined 
as the time that elapsed from the transplantation 
date until death, or the date of the last follow-up 
evaluation. For calculating graft survival, the date 
of graft removal was also considered. The patient 
and graft survival rate for the total and three 
different recipients was estimated by the Kaplan-
Meier method (24) and the comparison was done 
by the log-rank test (25). 
The median values for the daily FK 506 and 
Deltasone®, Vpjohn (prednisone) doses as well 
as the measured 12-hour'FK 506 trough plasma 
levels were calculated for each recipient for 30 
days at one, two, three, six, 12, and 24 months 
after transplantation. These median values were 
pooled in the three cohorts and the means (plus 
or minus standard error of the mean) were cal-
culated. 
Single variable comparison for qualitative (non-
survival) data was made by chi-square analysis. 
Kruskald Wallis' one-way analysis of variance was 
used for three-way comparison. The Mann-vVhit-
ney V-Wilcoxon test was used for independent 
variable analysis. 
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FIG. 5. a, Patient survival rate, all 43 recipients, and b, patient survival rate 
according to procedure. 
Patient survival. The follow-up period for the 
current survivors (n=30, 29 bearing grafts) is 
17 ± 9 SD months (range of six to 39 months). 
The actuarial survival rate for the 43 patients at 
three, six, 12, and 24 months is 88, 84, 81, and 
74 percent, respectively (Fig. 5a). The survival 
rate for the three cohorts is illustrated in Figure 
5b, with a mean follow-up period that is similar 
for all patients (p=0.7) (Table I). At three months, 
the survival rate for the isolated intestinal re-
cipients was 100 percent; 81 percent for those 
with combined hepatic and intestinal transplan-
tation, and 86 percent for the multivisceral re-
cipients. At one year after transplantation, these 
estimates were 93, 71, and 86 percent, respec-
392 Journal of the American College of Surgeons . October 1994 . Volume 179 
~ o 
-
co 
> 
> a-
::l 
en 
100 
80 
60 
_ 40 
-cu a-
t!) 
20 
N = 45 
• Alive 
• Dead 
A Graft Loss 
o+-~~~~~~~~~~~~~~~~~~~ 
-~ o 
-
cu 
> 
> a-
100 
80 
60 
~ 40 
-
-cu a-
t!) 20 
o 6 12 18 24 
Time After Transplantation (months) 
a 
• I 
.l'e.- - --1" .... __ ...... 
~ 
1 .. · .. ••••••••• .. •·• ... _-...., .. 
- Isolated Intestine (n=16) 
.... ..... Liver and Intestine (n=22) 
- - 0- - Multlvisceral (n=7) 
................................. 
o+-~~~~~~~~-K~~~~~~~~-I 
o 6 12 1 8 24 
Time After Transplantation (months) 
b 
FIG. 6. a, Graft survival rate, all 45 attempts including two retransplantations, 
and b, graft survival rate according to procedure. 
tively. At two years, the actuarial survival rate 
for the isolated intestinal recipients was 83 per-
cent, with 65 and 86 percent for those who re-
ceived combined hepatic and intestinal and mul-
tivisceral grafts, respectively. The isolated intestinal 
recipients had a significantly better survival time 
at two years than the recipients of liver and in-
testine (p=0.02), but this actuarial projection over-
stated the quality of the results. 
Graft survival. The estimated actuarial survival 
rate for all of the grafts (n=45) was 80, 78, 72, 
and 59 percent at three, six, 12, and 24 months, 
respectively (Figure 6a). Graft survival was highest 
at three months for the isolated intestine (88 
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TABLE IlL-TIME AND CAUSE OF DEATH 
Recipient 
Isolated intestine, n=15 
1 
3 
4 
Intestine plus liver, n=21 
1 
2 
3 
4 
5 
6 
7 
8 
Multivisceral, n=7 
I 
Case 
Adult 
Adult 
Adult 
Adult 
Child 
Child 
Child 
Child 
Child 
Adult 
Child 
Adult 
Adult 
Time, d Cause 
123 Adult respiratory distress syndrome 
376 Sepsis after removal of the graft 
4040 Pulmonary embolism due to caval 
thrombosis' 
776 Sepsis after removal of the second graft 
23 Enteric leak; graft versus host disease 
26 Respiratory syncytial viral pneumonia 
29 Biliary and enteric leak; sepsist 
70 Biliary leak; sepsis 
107 Acute rejection of the second graft 
356 Disseminated coccidioidomycosis 
385 Disseminated Iymphoproliferative disease 
752 Chronic rejection; hepatorenal failure 
49 Disseminated lymphoproliferative disease 
~red due to central line insertion 201 days after the removal of the rejected intestinal graft on postoperative day 239. 
tRequired liver replacement due to hepatic artery thrombosis. 
d. Day. 
percent) versus liver plus intestine (73 percent) 
and multivisceral cases (86 percent). However, 
by six months and at all subsequent times, the 
highest graft survival rate was in the multivisceral 
recipients. At 18 months, the rate was 86 percent 
compared with 64 percent in recipients of isolated 
intestines, and 62 percent in recipients of com-
bined hepatic and intestinal grafts (Fig. 6b), 
Causes of patient death. During potential follow-
up periods of six to 39 months, 13 (30 percent) 
of the 43 patients died: four of 15 receiving 
isolated intestine, eight of 21 receiving combined 
liver and intestine, and one of seven multivisceral. 
The deaths were the result of either technical 
complications, opportunistic infections, uncon-
trolled graft rejection, or disseminated post-trans-
plant lymphoproliferative disease (PTLD). Seven 
of these deaths occurred during, or shortly after, 
the first three months postoperatively, but six 
more were at or well beyond one year (Table 
III) . 
The four patients who died after isolated in-
testinal transplantation were adults. In three of 
these patients, an attempt was to remove the 
rejected grafts and return to TPN, whereas the 
fourth patient, who had been extremely debili-
tated before transplantation with active Crohn's 
disease, died as a result of respiratory failure 
with a functioning graft. 
In contrast, six of the eight ·mortalities after 
combined hepatic and intestinal transplantation 
were children. Enteric leaks, with or without bil-
iary leaks, were responsible for three deaths. The 
other three were caused by respiratory syncytial 
viral pneumonia, refractory acute rejection, or 
PTLD (one each). One of the two adult recipients 
of hepatic and intestinal transplantation died as 
a result of hepatorenal failure combined with 
TABLE N.-TIME, CAUSE AND OUTCOME OF GRAFT REMOVAL OR REPLACEMENT 
Graft Time, d Cause Procedure 
Isolated intestine, n=16 
I 27 Acute rejection* Enterectomy 
2 .. 239 Acute rejection* Enterectomy 
3 366 Acute rejection* Enterectomy 
4t .. 667 Chronic rejection" Enterectomy 
st .. 71 Acute rejection * Enterectomy 
Intestine plus liver, n=22 
1 11 Hepatic artery Retransplantation, liver only 
thrombosis 
2 47 Acute rejection Retransplantation, liver and 
intestine 
Multivisceral graft, n=7 
I 11 Severe pancreatitis Pancreatoduodenectomy 
~tion or withdrawal of immunosuppression precipitated rejection (see text). 
tSame recipien t. 
TPN, Total parenteral nutrition. 
Outcome 
Alive, on TPN 
Death, pulmonary embolism 
Death. sepsis 
Retransplan t 
Death. sepsis 
Death, sepsis 
Death, rejection 
Alive 
• 
, ; 
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TABLE V.-HEPATIC AND INTESTINAL i\LLOGRAFT REJECTION AMONG INTESTINAL RECIPIENTS 
Incidence 
-
Intestine_ 
Graft No. of grafts No. 
Isolated intestine . . .. · . · . 16 16 
Intestine plus liver 22 20 
Multivisceral . . . . . ... · . · . 5t 5 
Total . . . . . . . . . · . · .. 44 42 
·Number of grafts that required treatment. 
trhe multivisceral graft without a liver was excluded. 
Multivisceral: slomach, duodenUln, pancreas, intestine. and liver. 
Percent 
100 
91 
100 
95 
chronic rejection and the other died as a result 
of disseminated coccidioidomycosis. The latter was 
a California resident who contracted the disease 
during a coccidioidomycosis epidemic in her 
community, which also claimed three previously 
well non-transplant victims. The death that oc-
curred in the multivisceral series was caused by 
PTLD, which was diagnosed at autopsy 49 days 
post-transplantation, after having been misdiag-
nosed as rejection while the patient was alive, 
resulting in over treatment. 
Causes oj graft loss. Sixteen (six isolated intestine, 
nine liver and intestine and one multivisceral) 
of the 45 implanted grafts were lost either because 
of death (n=10) (Table III) or graft removal 
(n=6). The times, causes, and outcomes of graft 
removal or replacement are listed in Table N. 
Grafts removed-Refractory rejection was the 
reason for removal of all six grafts (five isolated 
intestine in four patients, one liver and intestine) 
(Table N). Two of the isolated intestinal grafts 
were received by the same adult. The first graft 
was lost at 667 days from chronic rejection after 
sporadic drug noncompliance, and the second 
was lost to acute rejection and concomitant CMV 
enteritis 71 days after retransplantation. This pa-
tient died as a result of multiple organ failure 
20 days after the second enterectomy. 
The rejected intestinal graft that was removed 
239 days after transplantation was in a recipient 
in whom immunosuppression was stopped be-
cause of a demyelinization neurologic syndrome. 
The patient fully recovered, only to die 29 weeks 
later as a result of a pulmonary embolism during 
an operation to replace a TPN line. 
An isolated intestinal graft was lost at 366 days 
because of a delay in treating acute rejection 
that was initially misdiagnosed as recurrent Crohn's 
disease. This patient died ten days after enterec-
tomyas a result of severe necrotizing pancreatitis 
and systemic infection. 
The intestinal graft that was lost from rejection 
at 27 days was in a child who received small 
-
Liver __ 
_ Episode/ graft_ _ Steroid recycle * _ OAT3* _ 
No. Percent Intestine Liver No. Percent No. Percent 
4.0 10 63 5 31 
10 45 3.8 0.86 10 45 1 5 
2 33 4.5 0.33 3 50 2 33 
12 43 4.1 0.50 23 52 8 18 
bowel plus half of the colon. Aggressive immu-
nosuppression was not possible because of a con-
comitant respiratory syncytial viral pneumonia and 
the graft was rejected. The patient is currently 
alive seven mon ths after returning to TPN. 
The only composite graft removed at reopera-
tion was a liver and intestine transplanted to a 
child across a strong positive cytotoxic cross-
match. Although graft removal and retransplan-
tation after 47 days was technically successful, 
refractory rejection of the second set of organs 
caused death after another 60 days. Thus, graft 
removal or replacement rescued only one of five 
patients in whom this was attempted. 
Grafts lost as a result of death-The causes 
of death were invariably multiple, but the prin-
cipal factors are given in Table III. 
Salvage of intestine by removal of other or-
gans-Loss of part of the composite graft oc-
curred in two patients because of either severe 
preservation injury of the pancreas necessitating 
pancreatectomy, or hepatic artery thrombosis ne-
cessitating hepatectomy (Table N). The multivis-
ceral graft recipient in whom the pancreas was 
lost is alive more than six months later, whereas 
the liver and intestine recipient who underwent 
total hepatectomy and hepatic replacement from 
another donor died 18 days later (Tables III 
and IV). 
Rejection. Only two patients (both with com-
bined liver and intestine) were spared clinical 
or histopathologic diagnosis9f intestinal graft 
rejection at some time postoperatively (Table V). 
The follow-up period in the two exceptional in-
stances was 23 days (when the patient died) and 
242 days (the patient is well). Although the clin-
ical diagnosis of rejection was made in 95 percent, 
this was confirmed histopathologically in only 31 
patients (72 percent). The diagnostic limitation 
of intestinal mucosal biopsies was underscored 
in some instances by finding rejection in the 
whole graft after its removal or at autopsy, after 
earlier inconclusive biopsy reports. ' 
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TABLE VI.-INFECTIOUS COMPLICATIONS AITER INTESTINAL TRANSPLANTATION 
__ Bacterial_ 
Recipient No. of pts. No. Episode/pI. 
Isolated intestine 15 12 1.8 
Inlestine plus liver 21 20 3.7 
Multivisceral 7 6 3.7 
Total 43 38 3.1 
Although the FK 506 doses, plasma trough lev-
els, and the prednisone doses were similar in 
the three types of allograft recipients (Fig. 4), 
the incidence of pathologically confirmed rejec-
tion was higher in the isolated intestine cases 
(93 percent) than in the liver and intestine (62 
percent) and multivisceral (57 percent) cases. 
Most of the rejections were graded mild to mod-
erate. The mean postoperative time to the first 
episode in all instances was 18.8 ± 28 days (range 
of three to 138 days); 10.7 ± 6 for the isolated 
intestine 22 ± 34 for the combined liver and in-
testine, and 15 ± 7 for the multivisceral allografts. 
Beyond three post-transplant months, about 50 
percent of the patients in each transplant group 
had rejection of the intestinal graft. This often 
was associated with attempts to reduce immuno-
suppression because of CMV enteritis, PTLD, or 
other opportunistic infections. Statistically, there 
was no significant difference between the three 
groups of intestinal recipients in the incidence, 
frequency, and severity of rejection, or the need 
for augmented steroids or OKT3 (Table V). 
Five (36 percent) of the 14 intestinal grafts, 
which included colon, showed histologic evidence 
of colonic rejection at some time. None of the 
multivisceral grafts had histopathologically proved 
gastric rejection, but one had two episodes of 
pancreatitis that responded to augmented steroid 
therapy. 
On 88 occasions in which both liver and small 
bowel biopsies were taken simultaneously or closely 
together, 47 (53 percent) of the dual specimens 
had no signs of rejection in either organ, 12 
(14 percent) had rejection in both, 15 (17 per-
cent) had rejection only in the liver, and 14 
(16 percent) had rejection in the intestine only. 
The histopathologic examination of full thickness 
sections of the six resected grafts showed chronic 
rejection in two of the isolated intestinal grafts. 
In addition, one combined liver and intestine 
recipient with strong positive cross-match had 
chronic rejection of both organs. This patient 
died as a result of hepatorenal failure with the 
graft in place. 
Infectious complications. Bacterial-Complications 
caused by enterococcus, Streptococcus jecium and 
__ Fungal __ _ Cytomegaloviral _ L ympllOproliferative disease, 
No. Episode/pt. No. Episode/pt. No. 
6 1.0 9 1.8 0 
8 1.3 5 1.6 3 
5 1.2 2 1.0 1 
19 1.2 16 1.5 4 
jaecalis, Enterobacter cloacae, coagulase negative and 
positive staphylococcus, Clostridium difficile and per-
fringens, Streptococcus viridans, Klebsiella, and Ac-
inetobacter anitratum were recorded on 114 occa-
sions in 38 (88 percent) of the 43 recipients 
(Table VI). The episodes included line sepsis, 
wound and intra-abdominal infections, pneumo-
nia, arthritis, colitis, urinary tract infection and 
bacteremia of unknown source. 
Fungal-Nineteen (44 percent) of the 43 re-
cipients had fungal infection of the esophagus, 
paranasal sinuses, trachea, lung, and peritoneum 
(Table VI), the highest incidence being in the 
multivisceral recipients (71 percent). The fungi 
were: Torulopsis glabrata, Candida albicans, 
Trichoderma koningii, and Coccidioides immitis. 
Translocation-The diagnosis of bacterial or fun-
gal translocation, or both, was made in patients 
who had the same microorganisms in the intestinal 
lumen and blood simultaneously with a quantitative 
stool culture count of more than lXl09 cfu per 
rnL. Thirteen episodes of translocation occurred 
in 11 recipients. Four (two adults and tWo children) 
of these were isolated intestinal reCipients and seven 
(two adults and five children) were combined liver 
and intestine recipients. Incongruously, there were 
no examples in the multivisceral cohort. The iso-
lated microorganisms were enterococcus, S. jecium 
and jaecalis, C. perfringens, coagulase negative staphy-
lococcus, Klebsiella, E. cloacae, C. (Jlbicans, and T. 
glabrata and in different combinations. Ten (77 
percent) of these episodes were associated with 
rejection. 
Cytomegaloviral-:-Sixteen (37 percent) intestinal 
recipients had at least one episode of new or re-
activated GMV infection (Table VI) 72 ± 63 days 
after transplantation (range of 21 to 128 days), 
enteritis (n=ll), hepatitis (n=2), pneumonitis (n=2), 
gastritis (n=l), retinitis (n=I), and CMV syndrome 
(n=I). Ten of these 16 morbid instances involved 
seronegative recipients who received seropositive 
grafts. Eight of these ten seropositive recipients 
were isolated intestinal recipients. The other two 
were combined liver and intestine and multivisceral 
recipients. Five of the CMV infected isolated in-
testinal recipients had graft rejection after reduction 
of immunosuppression and three of them had graft 
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TABLE VII.-POSTOPERATIVE COURSE AND CURRENT STATUS OF INTESTINAL RECIPIENTS 
Total population, n=43 Isolated intestine, n=15 Intestine·/iver, n=21 M ultivisceral, n=7 
Course* 
ICU stay, d · . 29±51 13±18 36±67 48±39 
En teral feeding started, d . 16±10 8±4 20±9 24±18 
TPN stopped, d 59±49 43±28 76±64 54±21 
Hospital stay, wk · . . . 12±8 1l±6 12±9 16±7 
Readmission, times. 4±4 3±3 5±4 4±4 
Curren t status, survivorst n=29 n=10 n=13 n=6 
Total parenteral nutrition 
Free 25 (86) 9 (90) 12 (92) 4 (67) 
Partial 
· . · . 
4 (14) 1 (10) 1 (8) 2 (33) 
Total 
· . · . 
0 (0) 0 (0) 0 (0) 0 (0) 
Location 
Home 
· . · . 
26 (90) 9 (90) 13 (100) 4 (66.7) 
Hospitalized . 
· . 
3 (10) 1 (10) 0 (0) 2 (33.3) 
~±paK 
ItGraft in place. 
Numbers in parentheses are percentages. 
ICU, Intensive care unit; TPN, total parenteral nutrition; d, day, and wk, week. 
removal. In contrast, there were no episodes of 
CMV infection in CMV seronegative recipients 
who received CMV seronegative grafts. 
Reactivation of CMV occurred in the remaining 
six patients, Four patients received seronegative 
and two received seropositive grafts. Four patients 
were combined liver and intestine recipients, one 
was isolated intestine, and the other was multivis-
ceral. 
Post-transplant lymphoproliferative disease-The 
occurrence of PTLD was histologically documented 
in four intestinal recipients (three children and 
one adult). The complication was diagnosed at 
49, 252, 287, and 383 days after transplantation 
and was fatal in two of the four patients. The 
PTLD involved both the native and transplanted 
organs. Treatment was attempted in the three 
pediatric patients with reduction of immunosup-
pression and initiation of antiviral therapy. In 
the adult, the disease was diagnosed at the time 
of autopsy. 
Acute Epstein-Barr viral (EBV) lymphadenitis 
occurred in another two patients, one combined 
liver and intestine pediatric recipient and one 
multivisceral adult recipient. Interestingly, the 
adult patient was successfully treated with triple 
antiviral therapy (gancyclovir, foscarnet, and al-
pha-interferon) despite augmentation of immu-
nosuppression because of simultaneous graft re-
jection. None of the isolated intestinal graft 
recipients had PTLD or EBV infections. 
Other viral infections-The pediatric recipients 
were more prone to other viral infections, which 
occurred in 12 patients on 17 occasions. The 
viral agents isolated were adenovirus, influenza 
and parainfluenza viruses, respiratory syncytial vi-
rus, rotavirus, and herpes simplex virus. 
Graft function. Nutrition-Total parenteral nu-
trition was discontinued for all recipients after 
18 to 210 days (59±49 oays) and tube feeding 
begun at three to 54 days (16 ± 10 days) after 
transplantation. The average overlap time be-
tween initiation of enteral feeding and discon-
tinuation of TPN was usually four weeks. The 
difference in timing between the three different 
recipients is given in Table VII. Interestingly, the 
isolated intestinal recipients tolerated enteral 
feeding significantly earlier than the· combined 
liver and intestine (p=O.OOOl) and multivisceral 
recipients (p=O.005). Most pediatric patients had 
failed to learn (or had forgotten) to eat. Oral 
feeding had to be taught. Few patients still prefer 
tube feeding to eating despite intensive rehabili-
tation~ Except for four patients (one isolated, 
one combined liver and intestine, and two mul-
tivisceral recipients), the other 25 current survi-
vors with gTaft in place are supported nutritionally 
solely with their functioning grafts. The four ex-
ceptional patients intermittently have been on 
partial TPN because of CMV enteritis, (n=l), gas-
tric atony because of progr~ssion of the primary 
gastroin testinal disease, "pseudo-obstruction" 
(n=l), or unexplained gastrointestinal dysmotility 
(n=2). The 30th patient had graft enterectomy. 
To date, all of the children except one gained 
body weight and had an increase in height (Fig. 
7a). Seven adult recipients (four multivisceral, 
two combined liver and intestine, and one iso-
lated intestine), lost 3 to 27 percent of their 
pretransplant body weight (Fig. 7b). The current 
values, however, are within the calculated ideal 
body weight for each individual. 
Gastrointestinal motility-Gastric emptying in 
the early postoperative period was delayed from 
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FIG. 7, a, Weight and height performance of children with intestinal graft in place, and b, 
weight performance of adult recipients. 
tvvo to 24 hours in 17 (85 percent) of the 20 
adult recipients studied, which was slight (more 
than three hours) in six and marked in 11 (more 
than six hours). Gastric hypoperistalsis frequently 
was associated with use of narcotic analgesics dur-
ing the early postoperative period. Recovery of 
the gastric motility was spontaneous and complete 
in all patients who were evaluated four to six 
months after transplantation. The mean intestinal 
transit time for the roentgenographically studied 
" j 
J 
i 
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transplanted intestine (n=21) was 4.1 ± 5.8 SD 
hours (range of 0.3 to 24 hours). Of these, 13 
(62 percent) had an abnormality of the intestinal 
transit time that was markedly accelerated (less 
than one hour) in six instances or prolonged 
(more than three hours) in the other seven. 
The mean intestinal transit time was 0.5 ± 0.2 
hours (range of 0.33 to 0.83 hours) and 9.4 ± 7.2 
hours (range of 3.25 to 24 hours) for each ab-
normality, respectively. Grafts with abnormal tran-
sit time were seven isolated intestine, four com-
bined liver and intestine, and two multivisceral. 
When studied later, these abnormalities were sig-
nificantly improved. 
In nine adult recipients, the myoelectric activity 
of the native and transplanted intestine was char-
acterized by measuring the migrating motor com-
plex (MMC). The antral motility was abnormal 
in all of the patients studied exhibited by decrease 
amplitude or frequency of contraction. Trans-
mission of contraction waves from native intestine 
to transplanted intestine occurred, although it 
was not always coordinated. Multivisceral trans-
plantation seemed to increase the likelihood of 
propagated MMC activity, as opposed to small 
bowel or liver and small bowel transplantation. 
Absorption-Complete oral administration of 
the standard FK 506 dose (0.3 mg per kg per 
day) was able to maintain the desired therapeutic 
plasma trough level of the drug for all patients 
by the end of the fourth postoperative week or 
earlier (Fig. 4). D-xylose was adequately absorbed 
by the intestinal graft in most of the patients 
studied (n=37) in the absence of significant pres-
ervation injury or graft rejection. Vitamin E ab-
sorption was slightly depressed in most of the 
patients (n=lO). The amount of the total fecal 
lipids was usually high in the early postoperative 
period, and fat absorption was still abnormal in 
some patients who were evaluated one year after 
transplantation. 
Disease recurrence-With follow-up periods 
ranging from eight to 22 months, none of the 
13 recipients who had chronic primary disease 
of the native intestine (including six patients with 
Crohn's disease) showed any clinical or histo-
pathologic evidences of disease recurrence in the 
visceral graft. 
Graft versus host disease. Using standard his-
tologic methods and in situ hybridization tech-
niques that allow distinction of donor from re-
cipient cells (26), graft versus host disease 
(GVHD) was unequivocally diagnosed in only one 
combined liver and intestine pediatric recipient. 
Because of Pneumocystis cannzz pneumonia and 
an intestinal anastomotic leak, light immunosup- .' 
pression was attempted early in the postoperative 
course of this child who had preexisting rgA 
deficiency. The skin lesions appeared ten days 
after transplantation. The overall clinical signs 
and symptoms simulated life-threatening sepsis. 
The immunosuppression was reduced signifi-
cantly, and 13 days later, the patient died as a 
result of multiple organ failure. 
Hospitalization. The early convalescence of most 
of the recipients was prolonged and complicated. 
With a median hospitalization period of 11 weeks 
(range of three to 45 weeks) after transplantation, 
recipients required staying in the intensive care 
unit (rCU) ranging from two to 300 days (median 
of 11 days). The mean values for the total popu-
lation and each group are given in Table VII. 
The isolated intestinal recipients required less 
time in the rcu compared with the combined 
liver and intestine (p=O.I) and multivisceral re-
cipients (p=0.004). During the study period, the 
median number of readmissions for all patients 
was three (range of zero to 14). The differences 
in mean values for each of the transplanted 
groups were not statistically significant (Table 
VII). The primary causes for prolonged hospi- .\; 
talization and frequent readmission were CMV 
enteritis, rejection, dehydration, postoperative pul- l 
monary insufficiency, EBV infections and PTLD. f 
Twenty-six (90 percent) of the 29 current sur-
vivors with graft in place are home and fully 
active, except one child who is permanently para-
plegic after a lumbar puncture. 
DISCUSSION 
Long-term survival after human intestinal trans-
plantation has been accomplished only in the 
last six years. The index transplantations were 
of a multivisceral graft in November 1987 (3), 
a combined liver and intestine in November 1988 
(4), a small intestinal seg~Kent from a living re-
lated donor in 1988 (5), and a cadaveric small 
bowel in 1989 (6). These sporadic achievements 1(, 
using cyclosporine based immunosuppression be-
came commonplace with all three procedures af- ( 
ter the demonstration by Murase and associates j 
of the superior potency of FK 506 in rat intestinal \ 
transplantation models (8, 9), and the prompt 1 
confirmation of these experimental results by oth- ;. 
ers (26-28). The ensuing clinical trials have been f 
described previously by Todo and Tzakis and J 
co-wo,km (10-13), fm which the p,esent cepo,t .. 
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has provided follow-up periods of six to 39 
months. 
Survival of most patients treated with each of 
the three intestinal transplant operations is jus-
tification for optimism. However, in this report, 
we have concentrated on the limitations and com-
plications of these procedures, which we believe 
preclude their widespread application without fur-
ther improvements in management. The prob-
lems have stemmed from the need for perfect 
and continuous control of rejection to maintain 
the barrier to alimentary contamination and to 
prevent translocation of bacteria and fungi. The 
necessarily continuous heavy immunosuppression 
is potentially self-defeating. This was exemplified 
by the fact that more than one-half of the deaths 
occurred within the first 120 days postoperatively. 
However, the most disappointing observatiofl was 
that, despite heavy immunosuppression, the threat 
of rejection remained exorbitantly high long after 
three months. Infectious and other complications 
that are related to rejection per se, as well as 
infections independent of the grafts, continued 
thereafter in the increasingly vulnerable recipi-
ents. Six more of the 13 deaths occurred at or 
well beyond one year. 
The effort and expense to care for this small 
collection of pioneer patients was prodigious, but 
without the sense of eventual security that often 
is achieved in the long surviving recipients of 
the liver alone. Having reached this conclusion, 
we have instituted a revised treatment strategy 
of perioperative bone marrow transplantation that 
would have been unthinkable at the time this 
program was begun because of the historic fear 
of GVHD associated experimentally with intestinal 
transplantation (29-31). However, in actual clin-
ical experience, GVHD has been seen in only 
one recipient who had an anastomotic (enteric) 
leak necessitating temporary discontinuance of 
immunosuppression. This patient also had preex-
isting IgA deficiency. 
In addition to these empiric observations of 
a minimal GVHD threat, much evidence has been 
uncovered in the last 18 months that the basis 
of acceptance of all kinds of grafts is the ubiq-
uitous migration of passenger leukocytes of bone 
marrow origin from transplanted organs with the 
occurrence of systemic chimerism and the grad-
ual induction of donor specific nonreactivity (32-
34). Thus, instead of causing GVHD under the 
therapeutic circumstances of whole organ trans-
plantation, the chimeric cells are apparently suf-
ficiently tolerogenic to be able to allow eventual 
drug weaning if they are present in sufficient 
quantities, as is the situation with the liver (33, 
35). 
Our revised protocol for future intestinal, liver 
and intestine, and multivisceral recipients is to 
augment this passenger leukocyte traffic with sup-
plementary bone marrow from the intestinal do-
nor, using the same perioperative immunosup-
pressive protocol as was created in the first 43 
cases. It remains to be seen if this approach will 
result in greater stability of the intestinal graft 
and its recipient, early and late after transplan-
tation. 
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